<p>Pirfenidone is a synthetic pyridone derivative that is primarily beneficial in treating idiopathic pulmonary fibrosis (IPF). Initially synthesized as an anti-inflammatory agent, it was later identified as the first oral antifibrotic therapy to improve progression-free survival in IPF, with an acceptable safety profile. Mechanistically, pirfenidone inhibits fibroblast proliferation, extracellular matrix deposition, and pro-inflammatory cytokine release by modulating the transforming growth factor-β (TGF-β) and its downstream pathways. Beyond IPF, emerging evidence suggests therapeutic potential across various fibrotic disorders related to aging, including systemic sclerosis-associated interstitial lung disease, cardiac fibrosis, uterine fibrosis, corneal fibrosis, liver fibrosis, intestinal fibrosis, wound healing, and lung cancer. However, high dose requirements and adverse events such as gastrointestinal intolerance and photosensitivity remain limiting factors of pirfenidone. To address these limitations, novel delivery systems, including lipid carriers, polymeric formulations, and other advanced systems, have been developed to enhance bioavailability, enable site-specific targeting, and sustain drug release over time. These developments underscore the evolving role of pirfenidone as a versatile antifibrotic therapy in the aging population with significant translational applications.</p> Graphical Abstract <p></p>